Current stem cell research & therapy最新文献

{"title":"Mesenchymal Stem Cell-derived Exosomes in the Treatment of End-stage Liver Disease.","authors":"Fa-Da Wang, En-Qiang Chen","doi":"10.2174/011574888X371122250613125926","DOIUrl":"10.2174/011574888X371122250613125926","url":null,"abstract":"<p><p>End-stage liver disease (ESLD) poses a significant threat to human health due to its high mortality rate. Although liver transplantation represents the most effective treatment modality, its application is limited by donor scarcity and prohibitive costs, thereby necessitating the development of innovative and efficacious therapeutic strategies. Within the realm of regenerative medicine, stem cell therapy has emerged as a promising alternative for ESLD treatment, with mesenchymal stem cells (MSCs) being at the forefront due to their exceptional multifunctional differentiation and self-renewal capabilities. Nonetheless, safety concerns, including the potential risk of tumorigenesis associated with MSCs, remain inadequately addressed. Recent evidence indicates that the therapeutic effects of MSCs are primarily mediated through paracrine mechanisms, with MSC-derived exosomes (MSC-Exos) serving as the principal effector mediators. The utilization of exosomes alone for therapeutic purposes not only preserves the beneficial effects of MSCs but also mitigates risks such as tumorigenic potential. Over the past few years, MSC-Exos have demonstrated significant ad-vancements across various medical disciplines, including cardiology, neurology, and gastroenterology. This review outlines the key mechanisms and recent progress in utilizing MSC-Exos in treating end-stage liver disease, seeking to highlight their unique therapeu- tic role.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"91-101"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FGF2-regulated Osteogenic Differentiation of Human Bone Marrow Stromal Cells.","authors":"Xianrui Yang, Nan E Hatch, Peter X Ma","doi":"10.2174/011574888X374305250703110356","DOIUrl":"10.2174/011574888X374305250703110356","url":null,"abstract":"<p><strong>Introduction: </strong>Fibroblast growth factor 2 (FGF2) plays a crucial role in regulating the osteogenic differentiation of progenitor cells. However, the process by which this occurs is not yet fully understood. In this study, we aimed to investigate whether FGF2 stimulates the osteogenesis of precursor cells through the yes-associated protein (YAP) and large tumor suppressor kinases 1/2 (LATS1/2).</p><p><strong>Methods: </strong>Human bone marrow stromal cells (hBMSCs) were cultured in osteogenic medium supplemented with FGF2 at concentrations of 2 ng/mL, 10 ng/mL, and 50 ng/mL for 2, 7, or 21 days. Alizarin red staining was performed to identify mineralization after 21 days of culture. RT-qPCR was conducted to detect the mRNA expression of Yap, Lats1, Lats2, Runx2, Bglap, and β-Actin. Immunofluorescence staining was carried out to detect the protein expression of YAP and LATS1/2. Data was analyzed with a p-value set at 0.05.</p><p><strong>Results: </strong>Mineralization was most significant at 10 ng/ml of FGF2 for 7 days and increased with concentrations of FGF2 from 0 ng/ml to 10 ng/ml for 7 days (p < 0.05) but decreased at the high concentration of 50 ng/ml for 2 days (p < 0.05). mRNA expression of Yap, Runx2, and Bglap increased in concordance with the increasing mineralization levels, but Lats1/2 mRNA decreased. mRNA expression levels were dose-dependent when FGF2 was added for 7 days (p < 0.05) and time-dependent when FGF2 concentration was at 10 ng/ml (p < 0.05). At the protein level, YAP increased while LATS1/2 decreased, indicating that LATS1/2 decreased, and YAP increased at higher mineralization levels when hBMSCs were cultured with 10 ng/ml of FGF2 for 7 days.</p><p><strong>Discussion: </strong>Consistent with our results, prior research has also indicated that lower concentrations of FGF2 enhance cell proliferation, thereby increasing the cell population for later osteogenic differentiation. However, excessive expansion can negatively affect differentiation. The mechanism of FGF2 regulation in stem cell osteogenic differentiation needs more exploration.</p><p><strong>Conclusion: </strong>Optimal concentrations and durations of FGF2 are critical for the osteogenic differentiation of hBMSCs. Moreover, it has been observed that mineralization correlates well with increasing YAP and decreasing LATS1/2 during osteogenic differentiation.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"159-171"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Examination of the Effects of Exosomes Generated from Bone Marrow Mesenchymal Stem Cells on Wound Healing (<i>In vitro</i> Study).","authors":"Zahra Karimzadeh, Saeedeh Zafar Balanezhad, Javad Baharara, Khadije Nejad Shahrokhabadi, Pejman Khorshid","doi":"10.2174/011574888X385954250819085742","DOIUrl":"10.2174/011574888X385954250819085742","url":null,"abstract":"<p><strong>Introduction: </strong>Exosomes produced by mesenchymal stem cells (MSCs) have lately garnered significant attention for their capacity to enhance wound healing. Recent studies have recognized exosomes as significant secretory products from several cell types, specifically MSCs, in regulating multiple biological processes, including wound healing. This work aims to investigate the impact of exosomes derived from the bone marrow mesenchymal stem cells (BMMSCs) of NMRI animals on keratinocyte function.</p><p><strong>Methods: </strong>Exosomes were extracted from BMMSCs using a flushing technique and afterwards cultivated. Stem cells were detected via flow cytometry, while exosomes were isolated and purified through ultracentrifugation. The exosomes were analyzed using various techniques, including scanning electron microscopy (SEM), atomic force microscopy (AFM), transmission electron microscopy (TEM), and dynamic light scattering (DLS). The MTT assay and trypan blue staining were employed to assess the effect of exosomes on keratinocyte viability. A scratch assay was performed to evaluate cell migration after treatment with exosomes. Real-time PCR was employed to evaluate the expression of genes such as KGF, MMP3, VEGF, and TGF-β3.</p><p><strong>Results: </strong>Keratinocytes exposed to 10 μg/mL of exosomes exhibited markedly enhanced viability relative to the control group. The group treated with exosomes had more cell migration compared to the control group. The therapy group had elevated expression levels of the KGF, MMP3, VEGF, and TGF-β3 genes.</p><p><strong>Discussion: </strong>The experimental findings indicate that exosomes derived from BMMSCs enhance keratinocyte viability, proliferation, migration, and gene expression.</p><p><strong>Conclusion: </strong>A comprehensive study of the factors affecting exosome generation, isolation, and mechanisms of action is crucial, as their potential use in wound healing facilitates the development of innovative and highly effective therapeutic strategies.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"292-301"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qishen Yiqi Dropping Pills Combined with Exosomes Alleviate Myocardial I/R Injury by Regulating Macrophage Polarization <i>via miRNA-155-5P</i>.","authors":"Weibin Qin, Liyan Yu, Weizhi Tang, Meng Wang, Lin Lin, Qingwei Zhang, Feifei Yang, Guixin He","doi":"10.2174/011574888X408846251007045430","DOIUrl":"10.2174/011574888X408846251007045430","url":null,"abstract":"<p><strong>Introduction: </strong>To investigate the protective mechanism of Qishen Yiqi Dropping Pills (Qishen) and its key active ingredients in combination with exosomes from bone marrow mesenchymal stem cells (BMSCs) against myocardial ischemia/reperfusion (I/R) injury.</p><p><strong>Methods: </strong>Infarct area was assessed by Evan's Blue/TTC double staining, myocardial apoptosis was analyzed by TUNEL staining, ATP content and NAD+/NADH ratio were detected biochemically, macrophage phenotype of myocardial tissues was detected by flow cytometry, activation of the mTOR/PI3K/Akt pathway was detected by Western blotting, and miR-155-5p expression was detected by qRT-PCR. 155-5p expression. Exo were given to identify the M1/M2 phenotypic transition by immunofluorescence, and the molecular mechanism was verified as in the in vivo experiments.</p><p><strong>Results: </strong>Compared with the model group, the Qishen, ginsenoside, and Exo group significantly reduced the infarcted area of the heart and promoted M2 and M2 phenotypic conversion, promoted M2- type macrophage infiltration, up-regulated the p-Akt/Akt ratio, and inhibited the expression of miR- 155-5p, but the combination therapy group did not show a synergistic effect, but the above protective effects were significantly weakened by the removal of macrophages. Ginsenoside and Exo synergistically promoted M2 polarization, activated the mTOR/PI3K/Akt pathway and upregulated miR-155-5p expression.</p><p><strong>Discussion: </strong>Qishen, particularly its active component ginsenoside, synergizes with BMSC-Exo to alleviate myocardial I/R injury by modulating macrophage polarization via the miR-155- 5p/mTOR/PI3K/Akt signaling axis.</p><p><strong>Conclusion: </strong>Qishen synergistically regulates the miR-155-5p/mTOR/PI3K/Akt signaling axis through ginsenoside components in BMSCs exosomes, promoting macrophage polarization toward M2-type, improving myocardial energy metabolism and attenuating I/R injury, and this protective effect is macrophage-dependent.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"316-331"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145380452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multipotent Mesenchymal Stromal Cells - A Promising Cytotherapeutic Agent for Breast Cancer.","authors":"Sankaranarayanan Srinivasan, Nalinkanth V Ghone, Hariharan Jayaraman, Maha Aruna Ashok","doi":"10.2174/011574888X398024250926100803","DOIUrl":"10.2174/011574888X398024250926100803","url":null,"abstract":"<p><p>Treating breast cancer has been quite a challenge due to drug resistance and the complexity of the tumor microenvironment. Moreover, the non-specificity of chemotherapeutic agents confers side effects while treating aggressive subtypes like triple-negative breast cancer. While targeted therapies are evolving, novel cellular therapies have a promising scope for treating breast cancer, as they can be tailored and allogeneic. Tailored cellular therapies face challenges such as cell availability and the cost of development as well as deployment. While allogeneic cellular therapies overcome these disadvantages, they face graft-versus-host disease. To overcome this, cells with no MHC-I and II, or less immunogenic cells with anti-cancer abilities, are attractive choices. One such cell type is the multipotent mesenchymal stromal cell (MSC). These cells are less immunogenic, have immunomodulatory properties, and are also known to home to tumor sites. Such properties can enable their exploitation for delivering drugs and other biotherapeutics. In addition, they seem to possess a natural tumor-inhibiting capability. However, it may be dependent on a multitude of factors, including cancer type, stage of presentation, and the tumor microenvironment. This review examines the fundamental biological mechanisms behind the anti-breast cancer effects of mesenchymal stem cells (MSCs), summarizes current advances in MSC-based therapeutic approaches for breast cancer, and explores the potential of genetically engineered MSCs in treatment, while identifying the existing research and application gaps.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"351-366"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Artificial Intelligence in Stem Cells and Gene Therapy for Gynecological Cancers.","authors":"Shiva Gholizadeh-Ghaleh Aziz, Sakineh Aghazadeh, Anosha Malik, Amir Javed, Sania Shaheen, Laiba Naseem, Younas Sohail, Aliasghar Tabatabaei Mohammadi, Muhammad Farrukh Nisar","doi":"10.2174/011574888X374002250707044343","DOIUrl":"10.2174/011574888X374002250707044343","url":null,"abstract":"<p><p>The application of artificial intelligence (AI) in stem cell and gene therapy offers significant advancements in the treatment of gynecological cancers, including breast, ovarian, and cervical cancers. This review explores how machine learning (ML) enhances both diagnostic and therapeutic strategies in regenerative medicine. AI integration allows for more accurate disease progression predictions, identification of therapeutic targets, and optimization of personalized treatment plans. Additionally, AI improves the efficacy and safety of stem cell and gene therapy approaches by facilitating the identification of biomarkers and genetic variations, enabling tailored therapies for individual patients. The use of AI-supported analytics in combined treatment strategies presents new avenues for effective cancer management. Furthermore, AI-driven regenerative medicine optimizes stem cell functions, refines treatment protocols, and contributes to the identification of less frequent biomarkers, improving prognostic algorithms and therapy outcomes. As ML targets specific molecular changes in cancer cells, they enhance the precision of gene silencing and anti-aging interventions, offering new possibilities for combined therapies. These innovations position AI as a transformative tool in the development of personalized and effective treatments for women's cancers, with future studies likely to expand the scope and impact of AI-driven strategies.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"102-120"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Hematopoietic Hierarchy: Emerging Insights into Megakaryocyte-biased Differentiation Pathways of Hematopoietic Stem Cells.","authors":"Ai Gao, Yuemin Gong","doi":"10.2174/011574888X395136250908045533","DOIUrl":"10.2174/011574888X395136250908045533","url":null,"abstract":"<p><p>Hematopoietic stem cells (HSCs) represent the most primitive cell population endowed with the ability for self-renewal and differentiation. They possess the capacity to differentiate into all types of blood cells, each serving unique functions. Traditional theories have established a clear hierarchical relationship between HSCs, their progenitors, and mature blood cells. The identification of distinct cell populations within the hematopoietic system forms the foundation of the hematopoietic differentiation model. However, recent research has led to a constant evolution of our understanding of the hierarchical structure of hematopoietic differentiation, particularly in the context of megakaryocyte differentiation pathways. Megakaryocytes are essential for platelet production, a critical process in hemostasis and thrombosis. Understanding the mechanisms underlying megakaryocyte-biased HSCs differentiation holds significance for both basic research and clinical applications. In this review, we consolidate the latest research progress concerning the evidence supporting these nonclassical pathways of megakaryocytic differentiation. Furthermore, we delve into the alterations observed in these pathways under conditions of steady state, transplantation, stress, and aging.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"367-376"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Cord Blood-derived Exosomes Enhance Chemosensitivity in Acute Myeloid Leukemia: A Promising Therapeutic Strategy.","authors":"Bahareh Abbaspanah, Fattah Sotoodehnejadnematalahi, Seyed Hadi Mousavi, Shaban Alizadeh","doi":"10.2174/011574888X393600250825163956","DOIUrl":"10.2174/011574888X393600250825163956","url":null,"abstract":"<p><strong>Introduction: </strong>Acute myeloid leukemia (AML) arises from the aberrant proliferation of white blood cells, red blood cells, or platelets. Various therapy modalities are available for individuals diagnosed with AML. While Cytarabine remains a standard treatment, exosomes, especially those derived from cord blood, have emerged as promising adjuncts. Exosomes are a specific kind of extracellular vesicles that have been identified as candidate biomolecules for the treatment of AML. The current study looked at how cord blood-derived exosomes affect the U937 cell lines compared to Cytarabine as a fundamental component of standard AML treatment.</p><p><strong>Methods: </strong>The first stage involved processing umbilical cord blood and isolating the mononuclear cells, CB-MNCs. The exosomes were isolated and verified using transmission electron microscopy, western blotting, and dynamic light scattering. Subsequently, for 72 hours, the U937 cells were cultivated and exposed to the exosomes, Cytarabine, and a combination of both. Afterward, apoptosis was evaluated using flow cytometry. The activity of Caspase 3/7 was assessed using a special kit. The real-time PCR technique was used to evaluate the gene expression in the proliferation and apoptosis pathways. Finally, the activity of NF-κB and AMPK was assessed using western blotting.</p><p><strong>Results: </strong>The flowcytometry analysis showed that the apoptosis rate of U937 cells after being exposed to CB-MNC exosomes, Cytarabine, and a mix of them was 19.60 (P < 0.05) %, 44.05 % (P < 0.0001), and 47.45 % (P < 0.0001), respectively. The activity of Caspase 3/7 was 0.32 mU/mL in the Cytarabine group and 0.45 mU/mL in the Mix group (P < 0.001). The qRT-PCR study revealed a notable upregulation of apoptotic genes and a downregulation of anti-apoptotic gene expression in the Mix group. Western blot analysis revealed a decrease in NF-κB phosphorylation in all treatment groups. In addition, the phosphorylation of AMPK increased in all treatment groups.</p><p><strong>Discussion: </strong>The study evaluated the effects of CB-MNC-derived exosomes on U937 cells, both alone and in combination with Cytarabine. Results demonstrated that while exosomes induced moderate apoptosis, their combination with Cytarabine significantly enhanced cell death, increased Caspase 3/7 activity, and altered gene expression in favor of apoptosis. The treatment also inhibited NF-κB and activated AMPK signaling pathways.</p><p><strong>Conclusion: </strong>In conclusion, our findings indicated that CB-MNC-derived exosomes together with Cytarabine have a cooperative effect on U937 cells through increasing apoptosis rate and reducing the proliferation rate, and may serve as a promising adjunct in AML therapy.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"302-315"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145288077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Notice to \"Expression and Function of PPARs in Cancer Stem Cells\".","authors":"Yiming Zhang, Xu Zhang, Jing Wang, Yun Shen, Xiaoshan Tang, Fang Yu, Raorao Wang","doi":"10.2174/1574888X20999250623123153","DOIUrl":"https://doi.org/10.2174/1574888X20999250623123153","url":null,"abstract":"<p><p>We regret to inform you that the article titled \"Expression and Function of PPARs in Cancer Stem Cells,\" published in Current Stem Cell Research & Therapy, Volume 11, Issue 3, 2016, is being retracted due to concerns regarding image manipulation and the reuse of images from unrelated studies by different authors, which depict findings from separate experiments. For example, Fig. (2) in the article appears to be identical to an image published in a study by Peters, J. et al. (2012), Nature Reviews Cancer, 12, 181-195 (https://doi.org/10.1038/nrc3214). When contacted for clarification, the authors were unable to provide the original/raw data to verify the authenticity of their results. In light of the lack of supporting evidence and the confirmed image duplication, the Editors have concluded that the findings of the article can no longer be considered reliable and have therefore recommended the retraction of the paper. We apologize for any inconvenience this may have caused and appreciate your understanding in this matter. Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure, or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication, the authors agree that the publishers have the legal right to take appropriate action against the authors if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Evaluation of Safety and Efficacy of Repeated Mesenchymal Stem Cell Transplantation in Patients with Amyotrophic Lateral Sclerosis (ALS) by Investigating Patient’s Specific microRNAs as Novel Biomarkers: A Clinical Trial Study","authors":"Zahraa Alkhazaali-Ali, Sajad Sahab-Negah, Amir Reza Boroumand, Najmeh Kaffash Farkhad, Mohammad Ali Khodadoust, Rashin Ganjali, Jalil Tavakol-Afshari","doi":"10.2174/011574888X330199250106081717","DOIUrl":"10.2174/011574888X330199250106081717","url":null,"abstract":"<p><p>Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn from the journal Current Stem Cell Research & Therapy.</p><p><p>The Publisher apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><p>The Bentham editorial policy on article withdrawal can be found at https://benthamscience.com/pages/editorial-policies-main</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}